Interestingly, targeting of CCR2 and MET resulted in the highest reduction in growth of mammary carcinomas, corresponding to a significant increase in cancer cell apoptosis, decreased cellular proliferation, as well as reduced stromal reactivity and inflammation in the microenvironment. The gene discussed is MET; the disease is breast carcinoma.